ITF, that is popular language, PPHM has been doing NOTHING of the sorts.
PPHM in 2012 took a lone. The Dose Switching incident with our CRO, CSM in Fargo, resulted in loan retraction and PPHM used the ATM to SAVE to company (or we would have had NOTHING any more) then salvage the 2nd ln NSCLC clinical trial and then get a Fast Track and finance a PIII.
That is something different then SELLING the company. They AUGMENTED the capital, capital that we find back in Avid expansion, new patents, collaborations, publications and pipeline extensions. So for the SOLD ATM shares we got things back that in time will leverage.
In an hostile acquisition one offers ASSET GRADE prices without potential value and that is what the PP avoids.
And furthermore I don't see what the problem is for most of you that say PPHM isn't worth anything. What do you care about the PP keeping potential candidates from acquiring PPHM in an hostile way if it REALLY has no value?
What an hostile idiot would want to acquire it? SO the PP doesn't harm if PPHM is really without value while it protects if, like I think with others, that it does has large potential value.
Again, SUNRISE is a slowdown and possibly an EXIT from CHEMO+Bavi, A good move because I-O moves to fast and will dominate the Oncology market in 5 years.
Market Data 
Markets 
AI
